Stephane De Cesco

Dr. Stephane De Cesco

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SCStephane De Cesco
Stephane De Cesco
JKJerry Kurian
Jerry Kurian
CDCaroline Dufresne
Caroline Dufresne
AMAnthony K. Mittermaier
Anthony K. Mittermaier
NMNicolas Moitessier
Nicolas Moitessier

28 June 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe ULTRA-DD Consortium
The ULTRA-DD Consortium
HFHai Fang
Hai Fang
HWHans De Wolf
Hans De Wolf
BKBogdan Knezevic
Bogdan Knezevic
KBKatie L. Burnham
Katie L. Burnham
JKJulian C. Knight
Julian C. Knight
Most candidate drugs currently fail later-stage clinical trials, largely due to poor prediction of efficacy on early target selection1. Drug targets with genetic support are more likely to be therapeutically valid2,3, but the translational use of genome-scale data such as from genome-wide association studies for drug target discovery in complex diseases remains challenging4,5,6. Here, we show that integration of functional genomic and immune-related annotations, together with knowledge of network connectivity, maximizes the informativeness of genetics for target validation, defining the target prioritization landscape for 30 immune traits at the gene and pathway level. We demonstrate how our genetics-led drug target prioritization approach (the priority index) successfully identifies current therapeutics, predicts activity in high-throughput cellular screens (including L1000, CRISPR, mutagenesis and patient-derived cell assays), enables prioritization of under-explored targets and allows for determination of target-level trait relationships. The priority index is an open-access, scalable system accelerating early-stage drug target selection for immune-mediated disease.

1 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JTJustin M. Di Trani
Justin M. Di Trani
SCStephane De Cesco
Stephane De Cesco
RORebecca O’leary
Rebecca O’leary
JPJessica Plescia
Jessica Plescia
CNClaudia Jorge Do Nascimento
Claudia Jorge Do Nascimento
Anthony MittermaierAnthony Mittermaier
Anthony Mittermaier
Although drug development typically focuses on binding thermodynamics, recent studies suggest that kinetic properties can strongly impact a drug candidate’s efficacy. Robust techniques for measuring inhibitor association and dissociation rates are therefore essential. To address this need, we have developed a pair of complementary isothermal titration calorimetry (ITC) techniques for measuring the kinetics of enzyme inhibition. The advantages of ITC over standard techniques include speed, generality, and versatility; ITC also measures the rate of catalysis directly, making it ideal for quantifying rapid, inhibitor-dependent changes in enzyme activity. We used our methods to study the reversible covalent and non-covalent inhibitors of prolyl oligopeptidase (POP). We extracted kinetics spanning three orders of magnitude, including those too rapid for standard methods, and measured sub-nM binding affinities below the typical ITC limit. These results shed light on the inhibition of POP and demonstrate the general utility of ITC-based enzyme inhibition kinetic measurements.

17 July 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SCStephane De Cesco
Stephane De Cesco
SDSébastien Deslandes
Sébastien Deslandes
ETEric Therrien
Eric Therrien
DLDavid Levan
David Levan
MCMickaël Cueto
Mickaël Cueto
NMNicolas Moitessier
Nicolas Moitessier

16 April 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HWHenriëtte Willems
Henriëtte Willems
SCStephane De Cesco
Stephane De Cesco
FSFredrik Svensson
Fredrik Svensson

15 February 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
MSMarion Schuller
Marion Schuller
TZTryfon Zarganes-Tzitzikas
Tryfon Zarganes-Tzitzikas
JBJames Bennett
James Bennett
SCStephane De Cesco
Stephane De Cesco
DFDaren Fearon
Daren Fearon
IAIvan Ahel
Ivan Ahel
The worldwide public health and socioeconomic consequences caused by the COVID-19 pandemic highlight the importance of increasing preparedness for viral disease outbreaks by providing rapid disease prevention and treatment strategies. The NSP3 macrodomain of coronaviruses including SARS-CoV-2 is among the viral protein repertoire that was identified as a potential target for the development of antiviral agents, due to its critical role in viral replication and consequent pathogenicity in the host. By combining virtual and biophysical screening efforts, we discovered several experimental small molecules and FDA-approved drugs as inhibitors of the NSP3 macrodomain. Analogue characterisation of the hit matter and crystallographic studies confirming binding modes, including that of the antibiotic compound aztreonam, to the active site of the macrodomain provide valuable structure–activity relationship information that support current approaches and open up new avenues for NSP3 macrodomain inhibitor development.